Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Research & Development (2021 - 2025)

Historic Research & Development for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $9.0 million.

  • SAB Biotherapeutics' Research & Development rose 1454.86% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.3 million, marking a year-over-year increase of 1542.35%. This contributed to the annual value of $30.3 million for FY2024, which is 8317.69% up from last year.
  • As of Q3 2025, SAB Biotherapeutics' Research & Development stood at $9.0 million, which was up 1454.86% from $7.0 million recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Research & Development peaked at $18.7 million during Q2 2021, and registered a low of $3.7 million during Q2 2023.
  • Over the past 5 years, SAB Biotherapeutics' median Research & Development value was $7.7 million (recorded in 2025), while the average stood at $8.6 million.
  • In the last 5 years, SAB Biotherapeutics' Research & Development crashed by 6595.91% in 2023 and then soared by 9480.83% in 2024.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Research & Development stood at $10.6 million in 2021, then plummeted by 32.96% to $7.1 million in 2022, then tumbled by 39.8% to $4.3 million in 2023, then skyrocketed by 78.05% to $7.7 million in 2024, then grew by 17.23% to $9.0 million in 2025.
  • Its Research & Development was $9.0 million in Q3 2025, compared to $7.0 million in Q2 2025 and $7.7 million in Q1 2025.